Video
Dr. Crawford on Sequences and Combinations in CRPC
Author(s):
E. David Crawford, MD, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.
E. David Crawford, MD, professor in Surgery and Radiation Oncology and the head of Urologic Oncology at the University of Colorado, Anschutz Medical Campus, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.
With so many newly approved agents, the challenge currently facing researchers is determining the appropriate sequence. Moreover, an even greater challenge, Crawford believes, will be discovering effective combinations.
Combination regimens have proven to be successful at curing patients with types of blood cancer, Crawford notes. Using this example, future trials in prostate cancer will explore the combination of an immunotherapy with other approved drugs in regimens of 3 to 4 agents. Researchers are excited by the broad potential available to expand the treatment of prostate cancer, Crawford says.
